2024 CCSNMMI Virtual Road Show: Bold Advanced Medical Future—Personalized Healthcare with Advanced Molecular Imaging

2024 CCSNMMI Virtual Road Show:
Bold Advanced Medical Future – Personalized Healthcare with Advanced Molecular Imaging
Saturday, November 9, 2024, 7:00am – 2:00pm Central
Register Now.

In our continued efforts to bring our members what they ask for, the Continuing Education Committee is taking you to the future of advanced molecular imaging.

Join us on Saturday, November 9th for presentations LIVE from Grand Rapids, Michigan and hear from leading nuclear medicine professionals from across the country. We are offering CME for Physicians and VOICE credits for Technologists.  You can stay as little or as long as you want.

Program Schedule: (Please note that times below are for the Central Time Zone.)

7-7:30am – Myocardial Perfusion PET Imaging: A Cardiologist’s Perspective, David Cameron, MD, Corewell Health

7:30-8am – The Scope of the Novel Clinical Trial Investigating O-15 Water PET in Coronary Artery Disease: Background and Scientific Evidence, Jens Sorensen, MD, Uppsala University Hospital

8-8:15am – Break

8:15-8:45am – Imaging Cancer through the Stroma- FAPI PET/CT, a Novel Tracer in Oncology, Sherly Mosessian, PhD, SOFIE

8:45-9:15am – Targeted Molecular Imaging: The Oncologist’s Perspective, Sreenivasa Chandana, MD, PhD, The Cancer & Hematology Centers

9:15-9:30am – Break

9:30-10am – Nuclear Medicine as the Pillar of Theranostics, Harshad Kulkarni, MD, BAMF Health

10-10:30am – NuMeMentor: Tomorrow’s Professionals, Fernando Anleu, CNMT, BAMF Health and Nichole Ozinga, CNMT, ARRT(N), NMTCB(PET), NMTCB(CT), Corewell Health

10:30 – 11am – Bridging the Gap: How Can Community Practices Offer Clinical Trials as an Advanced Care Option?, Deepak Behera, MD, PhD, Adaptive Research

11-11:30am – PSMA PET Imaging: A Urologist’s Perspective, Brian Lane, MD, PhD, Corewell Health

11:30am – 1pm – Lunch

1-1:30pm – PYL4301 Phase 4 Clinical Study (MIRROR) Assessing Piflufolastat F 18 PET Utility in Favorable Intermediate Risk Prostate Cancer: Background, Objectives, Study Design, and Implications, Roman Bilyk, MD, Lantheus

1:30-2pm – Novel Clinical Trial (Clarify) Investigating Cu-64 SAR-bis-PSMA: Background and Scientific Evidence, Erica Sztangret, Clarity Pharmaceuticals